Bausch + Lomb (NYSE:BLCO – Get Rating) had its target price increased by HC Wainwright from $19.00 to $22.00 in a report published on Friday morning, The Fly reports. BLCO has been the topic of a number of other research reports. JPMorgan Chase & Co. lifted their price objective on Bausch + Lomb from $15.00 […]
Bausch + Lomb (BLCO) and Novaliq Announce FDA Approval of MIEBO for Treatment of Signs and Symptoms of Dry Eye Disease streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
MIEBO is the First and Only Prescription Eye Drop Approved for Dry Eye Disease that Directly Targets Tear Evaporation, Based on Consistent Results from Two Consecutive Pivotal Phase 3 Trials Bausch